Vertex Pharmaceuticals Hits 20-Day High on Analyst Upgrades
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 03 Dec 25
Source: Business Insider
Vertex Pharmaceuticals Inc. saw a price increase of 4.71%, reaching a 20-day high amid positive market sentiment.
Recent analyst upgrades have highlighted the company's strong product pipeline and growth potential, contributing to investor confidence.
As Vertex continues to innovate and expand, these developments may lead to sustained interest from investors and further price appreciation.
Analyst Views on VRTX
Wall Street analysts forecast VRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRTX is 515.88 USD with a low forecast of 414.00 USD and a high forecast of 604.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
17 Buy
5 Hold
0 Sell
Strong Buy
Current: 477.910
Low
414.00
Averages
515.88
High
604.00
Current: 477.910
Low
414.00
Averages
515.88
High
604.00
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
